Misplaced Pages

Revision as of 18:32, 15 February 2024

Tourette syndrome
Other names	Tourette's syndrome, Tourette's disorder, Gilles de la Tourette syndrome (GTS), combined vocal and multiple motor tic disorder
Georges Gilles de la Tourette (1857–1904), namesake of Tourette syndrome
Specialty	Pediatrics, neurology, psychiatry
Symptoms	Tics
Usual onset	Typically in childhood
Duration	Long term
Causes	Genetic with environmental influence
Diagnostic method	Based on history and symptoms
Medication	Usually none, occasionally neuroleptics and noradrenergics
Prognosis	80% will experience improvement to disappearance of tics beginning in late teens
Frequency	About 1% of children and adolescents Between 0.3% and 1.0% of general population

Tourette syndrome or Tourette's syndrome (abbreviated as TS or Tourette's) is a common neurodevelopmental disorder that begins in childhood or adolescence. It is characterized by multiple movement (motor) tics and at least one vocal (phonic) tic. Common tics are blinking, coughing, throat clearing, sniffing, and facial movements. These are typically preceded by an unwanted urge or sensation in the affected muscles known as a premonitory urge, can sometimes be suppressed temporarily, and characteristically change in location, strength, and frequency. Tourette's is at the more severe end of a spectrum of tic disorders. The tics often go unnoticed by casual observers.

Tourette's was once regarded as a rare and bizarre syndrome and has popularly been associated with coprolalia (the utterance of obscene words or socially inappropriate and derogatory remarks). It is no longer considered rare; about 1% of school-age children and adolescents are estimated to have Tourette's, though coprolalia occurs only in a minority. There are no specific tests for diagnosing Tourette's; it is not always correctly identified, because most cases are mild, and the severity of tics decreases for most children as they pass through adolescence. Therefore, many go undiagnosed or may never seek medical attention. Extreme Tourette's in adulthood, though sensationalized in the media, is rare, but for a small minority, severely debilitating tics can persist into adulthood. Tourette's does not affect intelligence or life expectancy.

There is no cure for Tourette's and no single most effective medication. In most cases, medication for tics is not necessary, and behavioral therapies are the first-line treatment. Education is an important part of any treatment plan, and explanation alone often provides sufficient reassurance that no other treatment is necessary. Other conditions, such as attention deficit hyperactivity disorder (ADHD) and obsessive–compulsive disorder (OCD), are more likely to be present among those who are referred to specialty clinics than they are among the broader population of persons with Tourette's. These co-occurring conditions often cause more impairment to the individual than the tics; hence it is important to correctly distinguish co-occurring conditions and treat them.

Tourette syndrome was named by French neurologist Jean-Martin Charcot for his intern, Georges Gilles de la Tourette, who published in 1885 an account of nine patients with a "convulsive tic disorder". While the exact cause is unknown, it is believed to involve a combination of genetic and environmental factors. The mechanism appears to involve dysfunction in neural circuits between the basal ganglia and related structures in the brain.

Classification

Most published research on Tourette syndrome originates in the United States; in international TS research and clinical practice, the Diagnostic and Statistical Manual of Mental Disorders (DSM) is preferred over the World Health Organization (WHO) classification, which is criticized in the 2021 European Clinical Guidelines.

In the fifth version of the DSM (DSM-5), published in 2013, Tourette syndrome is classified as a motor disorder (a disorder of the nervous system that causes abnormal and involuntary movements). It is listed in the neurodevelopmental disorder category. Tourette's is at the more severe end of the spectrum of tic disorders; its diagnosis requires multiple motor tics and at least one vocal tic to be present for more than a year. Tics are sudden, repetitive, nonrhythmic movements that involve discrete muscle groups, while vocal (phonic) tics involve laryngeal, pharyngeal, oral, nasal or respiratory muscles to produce sounds. The tics must not be explained by other medical conditions or substance use.

Other tic disorders include persistent (chronic) motor or vocal tics, in which one type of tic (motor or vocal, but not both) has been present for more than a year; and provisional tic disorder, in which motor or vocal tics have been present for less than one year. The fifth edition of the DSM replaced what had been called transient tic disorder with provisional tic disorder, recognizing that "transient" can only be defined in retrospect. Some experts believe that TS and persistent (chronic) motor or vocal tic disorder should be considered the same condition, because vocal tics are also motor tics in the sense that they are muscular contractions of nasal or respiratory muscles.

Tourette syndrome is defined only slightly differently by the WHO; in its ICD-11, the International Statistical Classification of Diseases and Related Health Problems, Tourette syndrome is classified as a disease of the nervous system and a neurodevelopmental disorder, and only one motor tic is required for diagnosis. Older versions of the ICD called it "combined vocal and multiple motor tic disorder ".

Genetic studies indicate that tic disorders cover a spectrum that is not recognized by the clear-cut distinctions in the current diagnostic framework. Since 2008, studies have suggested that Tourette's is not a unitary condition with a distinct mechanism, as described in the existing classification systems. Instead, the studies suggest that subtypes should be recognized to distinguish "pure TS" from TS that is accompanied by attention deficit hyperactivity disorder (ADHD), obsessive–compulsive disorder (OCD) or other disorders, similar to the way that subtypes have been established for other conditions, such as type 1 and type 2 diabetes. Elucidation of these subtypes awaits fuller understanding of the genetic and other causes of tic disorders.

Characteristics

Tics

Tics are movements or sounds that take place "intermittently and unpredictably out of a background of normal motor activity", having the appearance of "normal behaviors gone wrong". The tics associated with Tourette's wax and wane; they change in number, frequency, severity, anatomical location, and complexity; each person experiences a unique pattern of fluctuation in their severity and frequency. Tics may also occur in "bouts of bouts", which also vary among people. The variation in tic severity may occur over hours, days, or weeks. Tics may increase when someone is experiencing stress, fatigue, anxiety, or illness, or when engaged in relaxing activities like watching TV. They sometimes decrease when an individual is engrossed in or focused on an activity like playing a musical instrument.

In contrast to the abnormal movements associated with other movement disorders, the tics of Tourette's are nonrhythmic, often preceded by an unwanted urge, and temporarily suppressible. Over time, about 90% of individuals with Tourette's feel an urge preceding the tic, similar to the urge to sneeze or scratch an itch. The urges and sensations that precede the expression of a tic are referred to as premonitory sensory phenomena or premonitory urges. People describe the urge to express the tic as a buildup of tension, pressure, or energy which they ultimately choose consciously to release, as if they "had to do it" to relieve the sensation or until it feels "just right". The urge may cause a distressing sensation in the part of the body associated with the resulting tic; the tic is a response that relieves the urge in the anatomical location of the tic. Examples of this urge are the feeling of having something in one's throat, leading to a tic to clear one's throat, or a localized discomfort in the shoulders leading to shrugging the shoulders. The actual tic may be felt as relieving this tension or sensation, similar to scratching an itch or blinking to relieve an uncomfortable feeling in the eye. Some people with Tourette's may not be aware of the premonitory urge associated with tics. Children may be less aware of it than are adults, but their awareness tends to increase with maturity; by the age of ten, most children recognize the premonitory urge.

Premonitory urges which precede the tic make suppression of the impending tic possible. Because of the urges that precede them, tics are described as semi-voluntary or "unvoluntary", rather than specifically involuntary; they may be experienced as a voluntary, suppressible response to the unwanted premonitory urge. The ability to suppress tics varies among individuals, and may be more developed in adults than children. People with tics are sometimes able to suppress them for limited periods of time, but doing so often results in tension or mental exhaustion. People with Tourette's may seek a secluded spot to release the suppressed urge, or there may be a marked increase in tics after a period of suppression at school or work. Children may suppress tics while in the doctor's office, so they may need to be observed when not aware of being watched.

Complex tics related to speech include coprolalia, echolalia and palilalia. Coprolalia is the spontaneous utterance of socially objectionable or taboo words or phrases. Although it is the most publicized symptom of Tourette's, only about 10% of people with Tourette's exhibit it, and it is not required for a diagnosis. Echolalia (repeating the words of others) and palilalia (repeating one's own words) occur in a minority of cases. Complex motor tics include copropraxia (obscene or forbidden gestures, or inappropriate touching), echopraxia (repetition or imitation of another person's actions) and palipraxia (repeating one's own movements).

Onset and progression

There is no typical case of Tourette syndrome, but the age of onset and the severity of symptoms follow a fairly reliable course. Although onset may occur anytime before eighteen years, the typical age of onset of tics is from five to seven, and is usually before adolescence. A 1998 study from the Yale Child Study Center showed that tic severity increased with age until it reached its highest point between ages eight and twelve. Severity declines steadily for most children as they pass through adolescence, when half to two-thirds of children see a dramatic decrease in tics.

In people with TS, the first tics to appear usually affect the head, face, and shoulders, and include blinking, facial movements, sniffing and throat clearing. Vocal tics often appear months or years after motor tics but can appear first. Among people who experience more severe tics, complex tics may develop, including "arm straightening, touching, tapping, jumping, hopping and twirling". There are different movements in contrasting disorders (for example, the autism spectrum disorders), such as self-stimulation and stereotypies.

The severity of symptoms varies widely among people with Tourette's, and many cases may be undetected. Most cases are mild and almost unnoticeable; many people with TS may not realize they have tics. Because tics are more commonly expressed in private, Tourette syndrome may go unrecognized, and casual observers might not notice tics. Most studies of TS involve males, who have a higher prevalence of TS than females, and gender-based differences are not well studied; a 2021 review suggested that the characteristics and progression for females, particularly in adulthood, may differ and better studies are needed.

Most adults with TS have mild symptoms and do not seek medical attention. While tics subside for the majority after adolescence, some of the "most severe and debilitating forms of tic disorder are encountered" in adults. In some cases, what appear to be adult-onset tics can be childhood tics re-surfacing.

Co-occurring conditions

Because people with milder symptoms are unlikely to be referred to specialty clinics, studies of Tourette's have an inherent bias towards more severe cases. When symptoms are severe enough to warrant referral to clinics, ADHD and OCD are often also found. In specialty clinics, 30% of those with TS also have mood or anxiety disorders or disruptive behaviors. In the absence of ADHD, tic disorders do not appear to be associated with disruptive behavior or functional impairment, while impairment in school, family, or peer relations is greater in those who have more comorbid conditions. When ADHD is present along with tics, the occurrence of conduct disorder and oppositional defiant disorder increases. Aggressive behaviors and angry outbursts in people with TS are not well understood; they are not associated with severe tics, but are connected with the presence of ADHD. ADHD may also contribute to higher rates of anxiety, and aggression and anger control problems are more likely when both OCD and ADHD co-occur with Tourette's.

Compulsions that resemble tics are present in some individuals with OCD; "tic-related OCD" is hypothesized to be a subgroup of OCD, distinguished from non-tic related OCD by the type and nature of obsessions and compulsions. Compared to the more typical compulsions of OCD without tics that relate to contamination, tic-related OCD presents with more "counting, aggressive thoughts, symmetry and touching" compulsions. Compulsions associated with OCD without tics are usually related to obsessions and anxiety, while those in tic-related OCD are more likely to be a response to a premonitory urge. There are increased rates of anxiety and depression in those adults with TS who also have OCD.

Among individuals with TS studied in clinics, between 2.9% and 20% had autism spectrum disorders, but one study indicates that a high association of autism and TS may be partly due to difficulties distinguishing between tics and tic-like behaviors or OCD symptoms seen in people with autism.

Not all people with Tourette's have ADHD or OCD or other comorbid conditions, and estimates of the rate of pure TS or TS-only vary from 15% to 57%; in clinical populations, a high percentage of those under care do have ADHD. Children and adolescents with pure TS are not significantly different from their peers without TS on ratings of aggressive behaviors or conduct disorders, or on measures of social adaptation. Similarly, adults with pure TS do not appear to have the social difficulties present in those with TS plus ADHD.

Among those with an older age of onset, more substance abuse and mood disorders are found, and there may be self-injurious tics. Adults who have severe, often treatment-resistant tics are more likely to also have mood disorders and OCD. Coprolalia is more likely in people with severe tics plus multiple comorbid conditions.

Neuropsychological function

There are no major impairments in neuropsychological function among people with Tourette's, but conditions that occur along with tics can cause variation in neurocognitive function. A better understanding of comorbid conditions is needed to untangle any neuropsychological differences between TS-only individuals and those with comorbid conditions.

Only slight impairments are found in intellectual ability, attentional ability, and nonverbal memory—but ADHD, other comorbid disorders, or tic severity could account for these differences. In contrast with earlier findings, visual motor integration and visuoconstructive skills are not found to be impaired, while comorbid conditions may have a small effect on motor skills. Comorbid conditions and severity of tics may account for variable results in verbal fluency, which can be slightly impaired. There might be slight impairment in social cognition, but not in the ability to plan or make decisions. Children with TS-only do not show cognitive deficits. They are faster than average for their age on timed tests of motor coordination, and constant tic suppression may lead to an advantage in switching between tasks because of increased inhibitory control.

Learning disabilities may be present, but whether they are due to tics or comorbid conditions is controversial; older studies that reported higher rates of learning disability did not control well for the presence of comorbid conditions. There are often difficulties with handwriting, and disabilities in written expression and math are reported in those with TS plus other conditions.

Causes

The exact cause of Tourette's is unknown, but it is well established that both genetic and environmental factors are involved. Genetic epidemiology studies have shown that Tourette's is highly heritable, and 10 to 100 times more likely to be found among close family members than in the general population. The exact mode of inheritance is not known; no single gene has been identified, and hundreds of genes are likely involved. Genome-wide association studies were published in 2013 and 2015 in which no finding reached a threshold for significance; a 2019 meta-analysis found only a single genome-wide significant locus on chromosome 13, but that result was not found in broader samples. Twin studies show that 50 to 77% of identical twins share a TS diagnosis, while only 10 to 23% of fraternal twins do. But not everyone who inherits the genetic vulnerability will show symptoms. A few rare highly penetrant genetic mutations have been found that explain only a small number of cases in single families (the SLITRK1, HDC, and CNTNAP2 genes).

Psychosocial or other non-genetic factors—while not causing Tourette's—can affect the severity of TS in vulnerable individuals and influence the expression of the inherited genes. Pre-natal and peri-natal events increase the risk that a tic disorder or comorbid OCD will be expressed in those with the genetic vulnerability. These include paternal age; forceps delivery; stress or severe nausea during pregnancy; and use of tobacco, caffeine, alcohol, and cannabis during pregnancy. Babies who are born premature with low birthweight, or who have low Apgar scores, are also at increased risk; in premature twins, the lower birthweight twin is more likely to develop TS.

Autoimmune processes may affect the onset of tics or exacerbate them. Both OCD and tic disorders are hypothesized to arise in a subset of children as a result of a post-streptococcal autoimmune process. Its potential effect is described by the controversial hypothesis called PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections), which proposes five criteria for diagnosis in children. PANDAS and the newer pediatric acute-onset neuropsychiatric syndrome (PANS) hypotheses are the focus of clinical and laboratory research, but remain unproven. There is also a broader hypothesis that links immune-system abnormalities and immune dysregulation with TS.

Some forms of OCD may be genetically linked to Tourette's, although the genetic factors in OCD with and without tics may differ. The genetic relationship of ADHD to Tourette syndrome, however, has not been fully established. A genetic link between autism and Tourette's has not been established as of 2017.

Mechanism

The exact mechanism affecting the inherited vulnerability to Tourette's is not well established. Tics are believed to result from dysfunction in cortical and subcortical brain regions: the thalamus, basal ganglia and frontal cortex. Neuroanatomic models suggest failures in circuits connecting the brain's cortex and subcortex; imaging techniques implicate the frontal cortex and basal ganglia. In the 2010s, neuroimaging and postmortem brain studies, as well as animal and genetic studies, made progress towards better understanding the neurobiological mechanisms leading to Tourette's. These studies support the basal ganglia model, in which neurons in the striatum are activated and inhibit outputs from the basal ganglia.

Cortico-striato-thalamo-cortical (CSTC) circuits, or neural pathways, provide inputs to the basal ganglia from the cortex. These circuits connect the basal ganglia with other areas of the brain to transfer information that regulates planning and control of movements, behavior, decision-making, and learning. Behavior is regulated by cross-connections that "allow the integration of information" from these circuits. Involuntary movements may result from impairments in these CSTC circuits, including the sensorimotor, limbic, language and decision making pathways. Abnormalities in these circuits may be responsible for tics and premonitory urges.

The caudate nuclei may be smaller in subjects with tics compared to those without tics, supporting the hypothesis of pathology in CSTC circuits in Tourette's. The ability to suppress tics depends on brain circuits that "regulate response inhibition and cognitive control of motor behavior". Children with TS are found to have a larger prefrontal cortex, which may be the result of an adaptation to help regulate tics. It is likely that tics decrease with age as the capacity of the frontal cortex increases. Cortico-basal ganglia (CBG) circuits may also be impaired, contributing to "sensory, limbic and executive" features. The release of dopamine in the basal ganglia is higher in people with Tourette's, implicating biochemical changes from "overactive and dysregulated dopaminergic transmissions".

Histamine and the H3 receptor may play a role in the alterations of neural circuitry. A reduced level of histamine in the H3 receptor may result in an increase in other neurotransmitters, causing tics. Postmortem studies have also implicated "dysregulation of neuroinflammatory processes".

Diagnosis

According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), Tourette's may be diagnosed when a person exhibits both multiple motor tics and one or more vocal tics over a period of one year. The motor and vocal tics need not be concurrent. The onset must have occurred before the age of 18 and cannot be attributed to the effects of another condition or substance (such as cocaine). Hence, other medical conditions that include tics or tic-like movements—for example, autism or other causes of tics—must be ruled out.

Patients referred for a tic disorder are assessed based on their family history of tics, vulnerability to ADHD, obsessive–compulsive symptoms, and a number of other chronic medical, psychiatric and neurological conditions. In individuals with a typical onset and a family history of tics or OCD, a basic physical and neurological examination may be sufficient. There are no specific medical or screening tests that can be used to diagnose Tourette's; the diagnosis is usually made based on observation of the individual's symptoms and family history, and after ruling out secondary causes of tic disorders (tourettism).

Delayed diagnosis often occurs because professionals mistakenly believe that TS is rare, always involves coprolalia, or must be severely impairing. The DSM has recognized since 2000 that many individuals with Tourette's do not have significant impairment; diagnosis does not require the presence of coprolalia or a comorbid condition, such as ADHD or OCD. Tourette's may be misdiagnosed because of the wide expression of severity, ranging from mild (in the majority of cases) or moderate, to severe (the rare but more widely recognized and publicized cases). About 20% of people with Tourette syndrome do not realize that they have tics.

Tics that appear early in the course of TS are often confused with allergies, asthma, vision problems, and other conditions. Pediatricians, allergists and ophthalmologists are among the first to see or identify a child as having tics, although the majority of tics are first identified by the child's parents. Coughing, blinking, and tics that mimic unrelated conditions such as asthma are commonly misdiagnosed. In the UK, there is an average delay of three years between symptom onset and diagnosis.

Differential diagnosis

• Yale Global Tic Severity Scale (YGTSS), recommended in international guidelines to assess "frequency, intensity, complexity, distribution, interference and impairment" of or due to tics
• Tourette Syndrome Clinical Global Impression (TS–CGI) and Shapiro TS Severity Scale (STSS), for a briefer assessment of tics than YGTSS
• Tourette's Disorder Scale (TODS), to assess tics and comorbidities
• Premonitory Urge for Tics Scale (PUTS), for individuals over age ten
• Motor tic, Obsessions and compulsions, Vocal tic Evaluation Survey (MOVES), to evaluate complex tics and other behaviors
• Autism—Tics, AD/HD, and other Comorbities (A–TAC), to screen for other conditions

Tics that may appear to mimic those of Tourette's—but are associated with disorders other than Tourette's—are known as tourettism and are ruled out in the differential diagnosis for Tourette syndrome. The abnormal movements associated with choreas, dystonias, myoclonus, and dyskinesias are distinct from the tics of Tourette's in that they are more rhythmic, not suppressible, and not preceded by an unwanted urge. Developmental and autism spectrum disorders may manifest tics, other stereotyped movements, and stereotypic movement disorder. The stereotyped movements associated with autism typically have an earlier age of onset; are more symmetrical, rhythmical and bilateral; and involve the extremities (for example, flapping the hands).

If another condition might better explain the tics, tests may be done; for example, if there is diagnostic confusion between tics and seizure activity, an EEG may be ordered. An MRI can rule out brain abnormalities, but such brain imaging studies are not usually warranted. Measuring thyroid-stimulating hormone blood levels can rule out hypothyroidism, which can be a cause of tics. If there is a family history of liver disease, serum copper and ceruloplasmin levels can rule out Wilson's disease. The typical age of onset of TS is before adolescence. In teenagers and adults with an abrupt onset of tics and other behavioral symptoms, a urine drug screen for stimulants might be requested.

Increasing episodes of tic-like behavior among teenagers (predominantly adolescent girls) were reported in several countries during the COVID-19 pandemic. Researchers linked their occurrence to followers of certain TikTok or YouTube artists. Described in 2006 as psychogenic, abrupt-onset movements resembling tics are referred to as a functional movement disorder or functional tic-like movements. Functional tic-like movements can be difficult to distinguish from tics that have an organic (rather than psychological) cause. They may occur alone or co-exist in individuals with tic disorders. These tics are inconsistent with the classic tics of TS in several ways: the premonitory urge (present in 90% of those with tics disorders) is absent in functional tic-like movements; the suppressibility seen in tic disorders is lacking; there is no family or childhood history of tics and there is a female predominance in functional tics, with a later-than-typical age of first presentation; onset is more abrupt than typical with movements that are more suggestible; and there is less co-occurring OCD or ADHD and more co-occurring disorders. Functional tics are "not fully stereotypical", do not respond to medications, do not demonstrate the classic waxing and waning pattern of Tourettic tics, and do not progress in the typical fashion, in which tics often first appear in the face and gradually move to limbs.

Other conditions that may manifest tics include Sydenham's chorea; idiopathic dystonia; and genetic conditions such as Huntington's disease, neuroacanthocytosis, pantothenate kinase-associated neurodegeneration, Duchenne muscular dystrophy, Wilson's disease, and tuberous sclerosis. Other possibilities include chromosomal disorders such as Down syndrome, Klinefelter syndrome, XYY syndrome and fragile X syndrome. Acquired causes of tics include drug-induced tics, head trauma, encephalitis, stroke, and carbon monoxide poisoning. The extreme self-injurious behaviors of Lesch-Nyhan syndrome may be confused with Tourette syndrome or stereotypies, but self-injury is rare in TS even in cases of violent tics. Most of these conditions are rarer than tic disorders and a thorough history and examination may be enough to rule them out without medical or screening tests.

Screening for other conditions

Although not all those with Tourette's have comorbid conditions, most presenting for clinical care exhibit symptoms of other conditions along with their tics. ADHD and OCD are the most common, but autism spectrum disorders or anxiety, mood, personality, oppositional defiant, and conduct disorders may also be present. Learning disabilities and sleep disorders may be present; higher rates of sleep disturbance and migraine than in the general population are reported. A thorough evaluation for comorbidity is called for when symptoms and impairment warrant, and careful assessment of people with TS includes comprehensive screening for these conditions.

Comorbid conditions such as OCD and ADHD can be more impairing than tics, and cause greater impact on overall functioning. Disruptive behaviors, impaired functioning, or cognitive impairment in individuals with comorbid Tourette's and ADHD may be accounted for by the ADHD, highlighting the importance of identifying comorbid conditions. Children and adolescents with TS who have learning difficulties are candidates for psychoeducational testing, particularly if the child also has ADHD.

Management

There is no cure for Tourette's. There is no single most effective medication, and no one medication effectively treats all symptoms. Most medications prescribed for tics have not been approved for that use, and no medication is without the risk of significant adverse effects. Treatment is focused on identifying the most troubling or impairing symptoms and helping the individual manage them. Because comorbid conditions are often a larger source of impairment than tics, they are a priority in treatment. The management of Tourette's is individualized and involves shared decision-making between the clinician, patient, family and caregivers. Practice guidelines for the treatment of tics were published by the American Academy of Neurology in 2019.

Education, reassurance and psychobehavioral therapy are often sufficient for the majority of cases. In particular, psychoeducation targeting the patient and their family and surrounding community is a key management strategy. Watchful waiting "is an acceptable approach" for those who are not functionally impaired. Symptom management may include behavioral, psychological and pharmacological therapies. Pharmacological intervention is reserved for more severe symptoms, while psychotherapy or cognitive behavioral therapy (CBT) may ameliorate depression and social isolation, and improve family support. The decision to use behavioral or pharmacological treatment is "usually made after the educational and supportive interventions have been in place for a period of months, and it is clear that the tic symptoms are persistently severe and are themselves a source of impairment in terms of self-esteem, relationships with the family or peers, or school performance".

Psychoeducation and social support

Knowledge, education and understanding are uppermost in management plans for tic disorders, and psychoeducation is the first step. A child's parents are typically the first to notice their tics; they may feel worried, imagine that they are somehow responsible, or feel burdened by misinformation about Tourette's. Effectively educating parents about the diagnosis and providing social support can ease their anxiety. This support can also lower the chance that their child will be unnecessarily medicated or experience an exacerbation of tics due to their parents' emotional state.

People with Tourette's may suffer socially if their tics are viewed as "bizarre". If a child has disabling tics, or tics that interfere with social or academic functioning, supportive psychotherapy or school accommodations can be helpful. Even children with milder tics may be angry, depressed or have low self-esteem as a result of increased teasing, bullying, rejection by peers or social stigmatization, and this can lead to social withdrawal. Some children feel empowered by presenting a peer awareness program to their classmates. It can be helpful to educate teachers and school staff about typical tics, how they fluctuate during the day, how they impact the child, and how to distinguish tics from naughty behavior. By learning to identify tics, adults can refrain from asking or expecting a child to stop ticcing, because "tic suppression can be exhausting, unpleasant, and attention-demanding and can result in a subsequent rebound bout of tics".

Adults with TS may withdraw socially to avoid stigmatization and discrimination because of their tics. Depending on their country's healthcare system, they may receive social services or help from support groups.

Behavioral

Behavioral therapies using habit reversal training (HRT) and exposure and response prevention (ERP) are first-line interventions in the management of Tourette syndrome, and have been shown to be effective. Because tics are somewhat suppressible, when people with TS are aware of the premonitory urge that precedes a tic, they can be trained to develop a response to the urge that competes with the tic. Comprehensive behavioral intervention for tics (CBIT) is based on HRT, the best researched behavioral therapy for tics. TS experts debate whether increasing a child's awareness of tics with HRT/CBIT (as opposed to ignoring tics) can lead to more tics later in life.

When disruptive behaviors related to comorbid conditions exist, anger control training and parent management training can be effective. CBT is a useful treatment when OCD is present. Relaxation techniques, such as exercise, yoga and meditation may be useful in relieving the stress that can aggravate tics. Beyond HRT, the majority of behavioral interventions for Tourette's (for example, relaxation training and biofeedback) have not been systematically evaluated and are not empirically supported.

Medication

Children with tics typically present when their tics are most severe, but because the condition waxes and wanes, medication is not started immediately or changed often. Tics may subside with education, reassurance and a supportive environment. When medication is used, the goal is not to eliminate symptoms. Instead, the lowest dose that manages symptoms without adverse effects is used, because adverse effects may be more disturbing than the symptoms being treated with medication.

The classes of medication with proven efficacy in treating tics—typical and atypical neuroleptics—can have long-term and short-term adverse effects. Some antihypertensive agents are also used to treat tics; studies show variable efficacy but a lower side effect profile than the neuroleptics. The antihypertensives clonidine and guanfacine are typically tried first in children; they can also help with ADHD symptoms, but there is less evidence that they are effective for adults. The neuroleptics risperidone and aripiprazole are tried when antihypertensives are not effective, and are generally tried first for adults. Because of lower side effects, aripiprazole is preferred over other antipsychotics. The most effective medication for tics is haloperidol, but it has a higher risk of side effects. Methylphenidate can be used to treat ADHD that co-occurs with tics, and can be used in combination with clonidine. Selective serotonin reuptake inhibitors are used to manage anxiety and OCD.

Other

Complementary and alternative medicine approaches, such as dietary modification, neurofeedback and allergy testing and control have popular appeal, but they have no proven benefit in the management of Tourette syndrome. Despite this lack of evidence, up to two-thirds of parents, caregivers and individuals with TS use dietary approaches and alternative treatments and do not always inform their physicians.

There is low confidence that tics are reduced with tetrahydrocannabinol, and insufficient evidence for other cannabis-based medications in the treatment of Tourette's. There is no good evidence supporting the use of acupuncture or transcranial magnetic stimulation; neither is there evidence supporting intravenous immunoglobulin, plasma exchange, or antibiotics for the treatment of PANDAS.

Deep brain stimulation (DBS) has become a valid option for individuals with severe symptoms that do not respond to conventional therapy and management, although it is an experimental treatment. Selecting candidates who may benefit from DBS is challenging, and the appropriate lower age range for surgery is unclear; it is potentially useful in less than 3% of individuals. The ideal brain location to target has not been identified as of 2019.

Pregnancy

A quarter of women report that their tics increase before menstruation; however, studies have not shown consistent evidence of a change in frequency or severity of tics related to pregnancy or hormonal levels. Overall, symptoms in women respond better to haloperidol than they do for men.

Most women find they can withdraw from medication during pregnancy without much trouble. When needed, medications are used at the lowest doses possible. During pregnancy, neuroleptic medications are avoided when possible because of the risk of pregnancy complications. When needed, olanzapine, risperidone and quetiapine are most often used as they have not been shown to cause fetal abnormalities. One report found that haloperidol could be used during pregnancy, to minimize the side effects in the mother, including low blood pressure, and anticholinergic effects, although it may cross the placenta.

If severe tics might interfere with administration of local anesthesia, other anesthesia options are considered. Neuroleptics in low doses may not affect the breastfed infant, but most medications are avoided. Clonidine and amphetamines may be present in breast milk.

Prognosis

Tourette syndrome is a spectrum disorder—its severity ranges from mild to severe. Symptoms typically subside as children pass through adolescence. In a group of ten children at the average age of highest tic severity (around ten or eleven), almost four will see complete remission by adulthood. Another four will have minimal or mild tics in adulthood, but not complete remission. The remaining two will have moderate or severe tics as adults, but only rarely will their symptoms in adulthood be more severe than in childhood.

Regardless of symptom severity, individuals with Tourette's have a normal life span. Symptoms may be lifelong and chronic for some, but the condition is not degenerative or life-threatening. Intelligence among those with pure TS follows a normal curve, although there may be small differences in intelligence in those with comorbid conditions. The severity of tics early in life does not predict their severity in later life. There is no reliable means of predicting the course of symptoms for a particular individual, but the prognosis is generally favorable. By the age of fourteen to sixteen, when the highest tic severity has typically passed, a more reliable prognosis might be made.

Tics may be at their highest severity when they are diagnosed, and often improve as an individual's family and friends come to better understand the condition. Studies report that almost eight out of ten children with Tourette's experience a reduction in the severity of their tics by adulthood, and some adults who still have tics may not be aware that they have them. A study that used video to record tics in adults found that nine out of ten adults still had tics, and half of the adults who considered themselves tic-free displayed evidence of mild tics.

Quality of life

People with Tourette's are affected by the consequences of tics and by the efforts to suppress them. Head and eye tics can interfere with reading or lead to headaches, and forceful tics can lead to repetitive strain injury. Severe tics can lead to pain or injuries; as an example, a rare cervical disc herniation was reported from a neck tic. Some people may learn to camouflage socially inappropriate tics or channel the energy of their tics into a functional endeavor.

A supportive family and environment generally give those with Tourette's the skills to manage the disorder. Outcomes in adulthood are associated more with the perceived significance of having tics as a child than with the actual severity of the tics. A person who was misunderstood, punished or teased at home or at school is likely to fare worse than a child who enjoyed an understanding environment. The long-lasting effects of bullying and teasing can influence self-esteem, self-confidence, and even employment choices and opportunities. Comorbid ADHD can severely affect the child's well-being in all realms, and extend into adulthood.

Factors impacting quality of life change over time, given the natural fluctuating course of tic disorders, the development of coping strategies, and a person's age. As ADHD symptoms improve with maturity, adults report less negative impact in their occupational lives than do children in their educational lives. Tics have a greater impact on adults' psychosocial function, including financial burdens, than they do on children. Adults are more likely to report a reduced quality of life due to depression or anxiety; depression contributes a greater burden than tics to adults' quality of life compared to children. As coping strategies become more effective with age, the impact of OCD symptoms seems to diminish.

Epidemiology

Tourette syndrome is a common but underdiagnosed condition that reaches across all social, racial and ethnic groups. It is three to four times more frequent in males than in females. Observed prevalence rates are higher among children than adults because tics tend to remit or subside with maturity and a diagnosis may no longer be warranted for many adults. Up to 1% of the overall population experiences tic disorders, including chronic tics and transient (provisional or unspecified) tics in childhood. Chronic tics affect 5% of children and transient tics affect up to 20%.

Many individuals with tics do not know they have tics, or do not seek a diagnosis, so epidemiological studies of TS "reflect a strong ascertainment bias" towards those with co-occurring conditions. The reported prevalence of TS varies "according to the source, age, and sex of the sample; the ascertainment procedures; and diagnostic system", with a range reported between 0.15% and 3.0% for children and adolescents. Sukhodolsky, et al. wrote in 2017 that the best estimate of TS prevalence in children was 1.4%. Both Robertson and Stern state that the prevalence in children is 1%. The prevalence of TS in the general population is estimated as 0.3% to 1.0%. According to turn of the century census data, these prevalence estimates translated to half a million children in the US with TS and half a million people in the UK with TS, although symptoms in many older individuals would be almost unrecognizable.

Tourette syndrome was once thought to be rare: in 1972, the US National Institutes of Health (NIH) believed there were fewer than 100 cases in the United States, and a 1973 registry reported only 485 cases worldwide. However, numerous studies published since 2000 have consistently demonstrated that the prevalence is much higher. Recognizing that tics may often be undiagnosed and hard to detect, newer studies use direct classroom observation and multiple informants (parents, teachers and trained observers), and therefore record more cases than older studies. As the diagnostic threshold and assessment methodology have moved towards recognition of milder cases, the estimated prevalence has increased.

Because of the high male prevalence of TS, there is limited data on females from which conclusion about gender-based differences can be drawn; caution may be warranted in extending conclusions to females regarding the characteristics and treatment of tics based on studies of mostly males. A 2021 review stated that females may see a later peak than males in symptoms, with less remission over time, along with a higher prevalence of anxiety and mood disorders.

History

A French doctor, Jean Marc Gaspard Itard, reported the first case of Tourette syndrome in 1825, describing the Marquise de Dampierre, an important woman of nobility in her time. In 1884, Jean-Martin Charcot, an influential French physician, assigned his student and intern Georges Gilles de la Tourette, to study patients with movement disorders at the Salpêtrière Hospital, with the goal of defining a condition distinct from hysteria and chorea. In 1885, Gilles de la Tourette published an account in Study of a Nervous Affliction of nine people with "convulsive tic disorder", concluding that a new clinical category should be defined. The eponym was bestowed by Charcot after and on behalf of Gilles de la Tourette, who later became Charcot's senior resident.

Following the 19th-century descriptions, a psychogenic view prevailed and little progress was made in explaining or treating tics until well into the 20th century. The possibility that movement disorders, including Tourette syndrome, might have an organic origin was raised when an encephalitis lethargica epidemic from 1918 to 1926 was linked to an increase in tic disorders.

During the 1960s and 1970s, as the beneficial effects of haloperidol on tics became known, the psychoanalytic approach to Tourette syndrome was questioned. The turning point came in 1965, when Arthur K. Shapiro—described as "the father of modern tic disorder research"—used haloperidol to treat a person with Tourette's, and published a paper criticizing the psychoanalytic approach. In 1975, The New York Times headlined an article with "Bizarre outbursts of Tourette's disease victims linked to chemical disorder in brain", and Shapiro said: "The bizarre symptoms of this illness are rivaled only by the bizarre treatments used to treat it."

During the 1990s, a more neutral view of Tourette's emerged, in which a genetic predisposition is seen to interact with non-genetic and environmental factors. The fourth revision of the DSM (DSM-IV) in 1994 added a diagnostic requirement for "marked distress or significant impairment in social, occupational, or other important areas of functioning", which led to an outcry from TS experts and researchers, who noted that many people were not even aware they had TS, nor were they distressed by their tics; clinicians and researchers resorted to using the older criteria in research and practice. In 2000, the American Psychiatric Association revised its diagnostic criteria in the fourth text revision of the DSM (DSM-IV-TR) to remove the impairment requirement, recognizing that clinicians often see people who have Tourette's without distress or impairment.

Society and culture

Not everyone with Tourette's wants treatment or a cure, especially if that means they may lose something else in the process. The researchers Leckman and Cohen believe that there may be latent advantages associated with an individual's genetic vulnerability to developing Tourette syndrome that may have adaptive value, such as heightened awareness and increased attention to detail and surroundings.

Accomplished musicians, athletes, public speakers and professionals from all walks of life are found among people with Tourette's. The athlete Tim Howard, described by the Chicago Tribune as the "rarest of creatures—an American soccer hero", and by the Tourette Syndrome Association as the "most notable individual with Tourette Syndrome around the world", says that his neurological makeup gave him an enhanced perception and an acute focus that contributed to his success on the field.

Samuel Johnson is a historical figure who likely had Tourette syndrome, as evidenced by the writings of his friend James Boswell. Johnson wrote A Dictionary of the English Language in 1747, and was a prolific writer, poet, and critic. There is little support for speculation that Mozart had Tourette's: the potentially coprolalic aspect of vocal tics is not transferred to writing, so Mozart's scatological writings are not relevant; the composer's available medical history is not thorough; the side effects of other conditions may be misinterpreted; and "the evidence of motor tics in Mozart's life is doubtful".

Likely portrayals of TS or tic disorders in fiction predating Gilles de la Tourette's work are "Mr. Pancks" in Charles Dickens's Little Dorrit and "Nikolai Levin" in Leo Tolstoy's Anna Karenina. The entertainment industry has been criticized for depicting those with Tourette syndrome as social misfits whose only tic is coprolalia, which has furthered the public's misunderstanding and stigmatization of those with Tourette's. The coprolalic symptoms of Tourette's are also fodder for radio and television talk shows in the US and for the British media. High-profile media coverage focuses on treatments that do not have established safety or efficacy, such as deep brain stimulation, and alternative therapies involving unstudied efficacy and side effects are pursued by many parents.

Research directions

Research since 1999 has advanced knowledge of Tourette's in the areas of genetics, neuroimaging, neurophysiology, and neuropathology, but questions remain about how best to classify it and how closely it is related to other movement or psychiatric disorders. Modeled after genetic breakthroughs seen with large-scale efforts in other neurodevelopmental disorders, three groups are collaborating in research of the genetics of Tourette's:

• The Tourette Syndrome Association International Consortium for Genetics (TSAICG)
• Tourette International Collaborative Genetics Study (TIC Genetics)
• European Multicentre Tics in Children Studies (EMTICS)

Compared to the progress made in gene discovery in certain neurodevelopmental or mental health disorders—autism, schizophrenia and bipolar disorder—the scale of related TS research is lagging in the United States due to funding.

Notes

1. According to Dale (2017), over time, 15% of people with tics have only TS (85% of people with Tourette's will develop a co-occurring condition). In a 2017 literature review, Sukhodolsky, et al. stated that 37% of individuals in clinical samples had pure TS. Denckla (2006) reported that a review of patient records revealed that about 40% of people with Tourette's have TS-only. Dure and DeWolfe (2006) reported that 57% of 656 individuals presenting with tic disorders had tics uncomplicated by other conditions.
2. There were no changes in the fifth text revision of 2022, DSM-5-TR.
3. The YGTSS is considered the gold standard in tic assessment.
4. Movement disorders without an organic cause have been referred to over time using terms such as hysterical, psychogenic and psychogenic movement disorders; DSM-5 classifies them under functional neurological symptom disorder/conversion disorder.
5. A prevalence range of 0.1% to 1% yields an estimate of 53,000 to 530,000 school-age children with Tourette's in the United States, using 2000 census data. In the United Kingdom, a prevalence estimate of 1.0% based on the 2001 census meant that about half a million people aged five or older would have Tourette's, although symptoms in older individuals would be almost unrecognizable. Prevalence rates in special education populations are higher.
6. The discrepancy between current and prior prevalence estimates arises from several factors: the ascertainment bias caused by samples that were drawn from clinically referred cases; assessment methods that failed to detect milder cases; and the use of different diagnostic criteria and thresholds. There were few broad-based community studies published before 2000, and most older epidemiological studies were based only on individuals referred to tertiary care or specialty clinics. People with mild symptoms may not have sought treatment and physicians may have avoided an official diagnosis of TS in children due to concerns about stigmatization. Studies are vulnerable to further error because tics vary in intensity and expression, are often intermittent, and are not always recognized by clinicians, individuals with TS, family members, friends or teachers.

References

1. ^ Müller-Vahl KR, Szejko N, Verdellen C, et al. (July 2021). "European clinical guidelines for Tourette syndrome and other tic disorders: summary statement". Eur Child Adolesc Psychiatry. 31 (3): 377–382. doi:10.1007/s00787-021-01832-4. PMC 8940881. PMID 34244849. S2CID 235781456.
2. ^ Stern JS (August 2018). "Tourette's syndrome and its borderland" (PDF). Pract Neurol (Historical review). 18 (4): 262–270. doi:10.1136/practneurol-2017-001755. PMID 29636375. Archived (PDF) from the original on December 1, 2018. Retrieved November 30, 2018.
3. ^ "Tourette syndrome fact sheet". National Institute of Neurological Disorders and Stroke. July 6, 2018. Archived from the original on December 1, 2018. Retrieved November 30, 2018.
4. ^ Hollis C, Pennant M, Cuenca J, et al. (January 2016). "Clinical effectiveness and patient perspectives of different treatment strategies for tics in children and adolescents with Tourette syndrome: a systematic review and qualitative analysis Archived June 3, 2022, at the Wayback Machine". Health Technology Assessment. Southampton (UK): NIHR Journals Library. 20 (4): 1–450. doi:10.3310/hta20040. ISSN 1366-5278.
5. ^ Szejko N, Robinson S, Hartmann A, et al. (October 2021). "European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part I: assessment". Eur Child Adolesc Psychiatry. 31 (3): 383–402. doi:10.1007/s00787-021-01842-2. PMC 8521086. PMID 34661764.
6. ^ Pringsheim T, Holler-Managan Y, Okun MS, et al. (May 2019). "Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders". Neurology (Review). 92 (19): 907–915. doi:10.1212/WNL.0000000000007467. PMC 6537130. PMID 31061209.
7. ^ Robertson MM, Eapen V (October 2014). "Tourette's: syndrome, disorder or spectrum? Classificatory challenges and an appraisal of the DSM criteria". Asian Journal of Psychiatry (Review). 11: 106–113. doi:10.1016/j.ajp.2014.05.010. PMID 25453712.
8. ^ Liu ZS, Cui YH, Sun D, et al. (2020). "Current status, diagnosis, and treatment recommendation for tic disorders in China". Front Psychiatry. 11: 774. doi:10.3389/fpsyt.2020.00774. PMC 7438753. PMID 32903695. The CCMD-3, DSM-5, and ICD-11 diagnostic criteria for tics are almost the same. Currently, the DSM-5 is mostly used in clinical practice around the world, including China.
9. ^ "Tourette's Disorder, 307.23 (F95.2)". Diagnostic and Statistical Manual of Mental Disorders (5th ed.). American Psychiatric Association. 2013. p. 81.
10. Martino D, Hedderly T (February 2019). "Tics and stereotypies: A comparative clinical review". Parkinsonism Relat. Disord. (Review). 59: 117–124. doi:10.1016/j.parkreldis.2019.02.005. PMID 30773283. S2CID 73486351.
11. ^ Martino D, Pringsheim TM (February 2018). "Tourette syndrome and other chronic tic disorders: an update on clinical management". Expert Rev Neurother (Review). 18 (2): 125–137. doi:10.1080/14737175.2018.1413938. PMID 29219631. S2CID 205823966.
12. Jankovic J (September 2017). "Tics and Tourette syndrome" (PDF). Practical Neurology: 22–24. Archived from the original (PDF) on March 24, 2019. Retrieved March 24, 2019.
13. ^ Fernandez TV, State MW, Pittenger C (2018). "Tourette disorder and other tic disorders". Neurogenetics, Part I (Review). Handbook of Clinical Neurology. Vol. 147. pp. 343–354. doi:10.1016/B978-0-444-63233-3.00023-3. ISBN 978-0-444-63233-3. PMID 29325623.
14. ^ Dale RC (December 2017). "Tics and Tourette: a clinical, pathophysiological and etiological review". Curr. Opin. Pediatr. (Review). 29 (6): 665–673. doi:10.1097/MOP.0000000000000546. PMID 28915150. S2CID 13654194.
15. ^ Sukhodolsky et al. (2017), p. 242.
16. "Neurodevelopmental disorders". American Psychiatric Association. Archived from the original on May 10, 2011. Retrieved December 29, 2011.
17. "Highlights of changes from DSM-IV-TR to DSM-5" (PDF). American Psychiatric Association. 2013. Archived from the original (PDF) on February 3, 2013. Retrieved June 5, 2013.
18. Reed GM, First MB, Kogan CS, et al. (February 2019). "Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders". World Psychiatry. 18 (1): 3–19. doi:10.1002/wps.20611. PMC 6313247. PMID 30600616. Finally, chronic tic disorders, including Tourette syndrome, are classified in the ICD-11 chapter on diseases of the nervous system, but are cross-listed in the grouping of neurodevelopmental disorders because of their high co-occurrence (e.g., with ADHD) and typical onset during the developmental period.
19. "8A05.00 Tourette syndrome". World Health Organization. Archived from the original on August 1, 2018. Retrieved March 28, 2022. Diseases of the nervous system --> Tic disorders: "onset during the developmental period"
20. ^ Ueda K, Black KJ (2021). "Recent progress on Tourette syndrome". Fac Rev. 10: 70. doi:10.12703/r/10-70. PMC 8442002. PMID 34557874.
21. "International Statistical Classification of Diseases and Related Health Problems 10th Revision: Chapter V: Mental and behavioural disorders". World Health Organization. 2010. Archived from the original on March 31, 2020. Retrieved August 7, 2020. See also ICD version 2007. Archived March 4, 2012, at the Wayback Machine
22. ^ "Definitions and classification of tic disorders. The Tourette Syndrome Classification Study Group". Arch. Neurol. (Research support). 50 (10): 1013–1016. October 1993. doi:10.1001/archneur.1993.00540100012008. PMID 8215958. Archived from the original on April 26, 2006.
23. ^ Dure LS, DeWolfe J (2006). "Treatment of tics". Adv Neurol (Review). 99: 191–196. PMID 16536366.
24. ^ Hashemiyoon R, Kuhn J, Visser-Vandewalle V (January 2017). "Putting the pieces together in Gilles de la Tourette Syndrome: exploring the link between clinical observations and the biological basis of dysfunction". Brain Topogr (Review). 30 (1): 3–29. doi:10.1007/s10548-016-0525-z. PMC 5219042. PMID 27783238.
25. ^ Ludlow AK, Rogers SL (March 2018). "Understanding the impact of diet and nutrition on symptoms of Tourette syndrome: A scoping review". J Child Health Care (Review). 22 (1): 68–83. doi:10.1177/1367493517748373. hdl:2299/19887. PMID 29268618.
26. ^ Sukhodolsky et al. (2017), p. 243.
27. ^ Jankovic J (2001). "Differential diagnosis and etiology of tics". Adv Neurol (Review). 85: 15–29. PMID 11530424.
28. ^ Prado HS, Rosário MC, Lee J, Hounie AG, Shavitt RG, Miguel EC (May 2008). "Sensory phenomena in obsessive-compulsive disorder and tic disorders: a review of the literature". CNS Spectr (Review and meta-anlysis). 13 (5): 425–432. doi:10.1017/s1092852900016606. PMID 18496480. S2CID 5694160. Archived from the original on February 10, 2012.
29. Bliss J (December 1980). "Sensory experiences of Gilles de la Tourette syndrome". Arch. Gen. Psychiatry. 37 (12): 1343–1347. doi:10.1001/archpsyc.1980.01780250029002. PMID 6934713.
30. ^ Kwak C, Dat Vuong K, Jankovic J (December 2003). "Premonitory sensory phenomenon in Tourette's syndrome". Mov. Disord. 18 (12): 1530–1533. doi:10.1002/mds.10618. PMID 14673893. S2CID 8152205.
31. ^ Swain JE, Scahill L, Lombroso PJ, King RA, Leckman JF (August 2007). "Tourette syndrome and tic disorders: a decade of progress". J Am Acad Child Adolesc Psychiatry (Review). 46 (8): 947–968. doi:10.1097/chi.0b013e318068fbcc. PMID 17667475. S2CID 343916.
32. ^ Ludolph AG, Roessner V, Münchau A, Müller-Vahl K (November 2012). "Tourette syndrome and other tic disorders in childhood, adolescence and adulthood". Dtsch Ärztebl Int (Review). 109 (48): 821–828. doi:10.3238/arztebl.2012.0821. PMC 3523260. PMID 23248712.
33. ^ Müller-Vahl (2013), p. 629.
34. ^ Black KJ (March 30, 2007). "Tourette syndrome and other tic disorders". eMedicine. Archived from the original on August 22, 2009. Retrieved August 10, 2009.
35. ^ Singer HS (2011). "Tourette syndrome and other tic disorders". Hyperkinetic Movement Disorders (Historical review). Handbook of Clinical Neurology. Vol. 100. Elsevier. pp. 641–657. doi:10.1016/B978-0-444-52014-2.00046-X. ISBN 978-0-444-52014-2. PMID 21496613. Also see Singer HS (March 2005). "Tourette's syndrome: from behaviour to biology". Lancet Neurol (Review). 4 (3): 149–59. doi:10.1016/S1474-4422(05)01012-4. PMID 15721825. S2CID 20181150.
36. ^ Leckman JF, Bloch MH, King RA, Scahill L (2006). "Phenomenology of tics and natural history of tic disorders". Adv Neurol (Historical review). 99: 1–16. PMID 16536348.
37. ^ Zinner SH (November 2000). "Tourette disorder". Pediatr Rev (Review). 21 (11): 372–383. doi:10.1542/pir.21-11-372. PMID 11077021. S2CID 7774922.
38. ^ Leckman JF, Zhang H, Vitale A, et al. (July 1998). "Course of tic severity in Tourette syndrome: the first two decades" (PDF). Pediatrics (Research support). 102 (1 Pt 1): 14–19. doi:10.1542/peds.102.1.14. PMID 9651407. S2CID 24743670. Archived from the original (PDF) on January 13, 2012.
39. ^ Fernandez TV, State MW, Pittenger C (2018). "Tourette disorder and other tic disorders". Neurogenetics, Part I (Review). Handbook of Clinical Neurology. Vol. 147. pp. 343–354. doi:10.1016/B978-0-444-63233-3.00023-3. ISBN 978-0-444-63233-3. PMID 29325623. Citing Bloch (2013), p. 109: No tics when they reach adulthood, 37%; minimal 18%; mild 26%; moderate 14%; worse 5%.
40. ^ Rapin I (2001). "Autism spectrum disorders: relevance to Tourette syndrome". Adv Neurol (Review). 85: 89–101. PMID 11530449.
41. ^ Robertson MM (February 2011). "Gilles de la Tourette syndrome: the complexities of phenotype and treatment". Br J Hosp Med (Lond). 72 (2): 100–107. doi:10.12968/hmed.2011.72.2.100. PMID 21378617.
42. ^ Robertson MM (November 2008). "The prevalence and epidemiology of Gilles de la Tourette syndrome. Part 1: the epidemiological and prevalence studies". J Psychosom Res (Review). 65 (5): 461–472. doi:10.1016/j.jpsychores.2008.03.006. PMID 18940377.
43. ^ Knight T, Steeves T, Day L, Lowerison M, Jette N, Pringsheim T (August 2012). "Prevalence of tic disorders: a systematic review and meta-analysis". Pediatr. Neurol. (Review). 47 (2): 77–90. doi:10.1016/j.pediatrneurol.2012.05.002. PMID 22759682.
44. Kenney C, Kuo SH, Jimenez-Shahed J (March 2008). "Tourette's syndrome". Am Fam Physician (Review). 77 (5): 651–658. PMID 18350763.
45. Black KJ, Black ER, Greene DJ, Schlaggar BL (2016). "Provisional Tic Disorder: What to tell parents when their child first starts ticcing". F1000Res (Review). 5: 696. doi:10.12688/f1000research.8428.1. PMC 4850871. PMID 27158458.
46. ^ Garris J, Quigg M (October 2021). "The female Tourette patient: sex differences in Tourette disorder". Neurosci Biobehav Rev (Review). 129: 261–268. doi:10.1016/j.neubiorev.2021.08.001. PMID 34364945. S2CID 236921688.
47. ^ Robertson MM, Eapen V, Singer HS, et al. (February 2017). "Gilles de la Tourette syndrome" (PDF). Nat Rev Dis Primers (Review). 3 (1): 16097. doi:10.1038/nrdp.2016.97. PMID 28150698. S2CID 38518566. Archived (PDF) from the original on July 22, 2018. Retrieved April 22, 2020.
48. Kammer T (2007). "Mozart in the neurological department – who has the tic?" (PDF). In Bogousslavsky J, Hennerici MG (eds.). Neurological Disorders in Famous Artists - Part 2 (Historical biography). Frontiers of Neurology and Neuroscience. Vol. 22. Basel: Karger. pp. 184–192. doi:10.1159/000102880. ISBN 978-3-8055-8265-0. PMID 17495512. Archived from the original (PDF) on February 7, 2012.
49. Todd O (2005). Malraux: A Life. Alfred A. Knopf. p. 7. ISBN 978-0375407024.
50. Guidotti TL (May 1985). "André Malraux: a medical interpretation". J R Soc Med (Historical biography). 78 (5): 401–406. doi:10.1177/014107688507800511. PMC 1289723. PMID 3886907.
51. ^ Bloch M, State M, Pittenger C (April 2011). "Recent advances in Tourette syndrome". Curr. Opin. Neurol. (Review). 24 (2): 119–125. doi:10.1097/WCO.0b013e328344648c. PMC 4065550. PMID 21386676.
52. See also
    • Schapiro NA (2002). ""Dude, you don't have Tourette's:" Tourette's syndrome, beyond the tics". Pediatr Nurs (Review). 28 (3): 243–246, 249–53. PMID 12087644. Archived from the original on December 5, 2008.
    • Coffey BJ, Park KS (May 1997). "Behavioral and emotional aspects of Tourette syndrome". Neurol Clin (Review). 15 (2): 277–89. doi:10.1016/s0733-8619(05)70312-1. PMID 9115461.
53. ^ Hirschtritt ME, Lee PC, Pauls DL, et al. (April 2015). "Lifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in Tourette syndrome". JAMA Psychiatry. 72 (4): 325–333. doi:10.1001/jamapsychiatry.2014.2650. PMC 4446055. PMID 25671412.
54. ^ Scahill L, Williams S, Schwab-Stone M, Applegate J, Leckman JF (2006). "Disruptive behavior problems in a community sample of children with tic disorders". Adv Neurol (Comparative study). 99: 184–190. PMID 16536365.
55. ^ Morand-Beaulieu S, Leclerc JB, Valois P, et al. (August 2017). "A review of the neuropsychological dimensions of Tourette syndrome". Brain Sci (Review). 7 (8): 106. doi:10.3390/brainsci7080106. PMC 5575626. PMID 28820427.
56. ^ Sukhodolsky et al. (2017), p. 245.
57. Hounie AG, do Rosario-Campos MC, Diniz JB, et al. (2006). "Obsessive-compulsive disorder in Tourette syndrome". Adv Neurol (Review). 99: 22–38. PMID 16536350.
58. Katz TC, Bui TH, Worhach J, Bogut G, Tomczak KK (2022). "Tourettic OCD: Current understanding and treatment challenges of a unique endophenotype". Front Psychiatry. 13: 929526. doi:10.3389/fpsyt.2022.929526. PMC 9363583. PMID 35966462.
59. Cravedi E, Deniau E, Giannitelli M, et al. (2017). "Tourette syndrome and other neurodevelopmental disorders: a comprehensive review". Child Adolesc Psychiatry Ment Health (Review). 11 (1): 59. doi:10.1186/s13034-017-0196-x. PMC 5715991. PMID 29225671.
60. Darrow SM, Grados M, Sandor P, et al. (July 2017). "Autism spectrum symptoms in a Tourette's disorder sample". J Am Acad Child Adolesc Psychiatry (Comparative study). 56 (7): 610–617.e1. doi:10.1016/j.jaac.2017.05.002. PMC 5648014. PMID 28647013.
61. ^ Sukhodolsky et al. (2017), p. 244.
62. Denckla MB (August 2006). "Attention-deficit hyperactivity disorder (ADHD) comorbidity: a case for "pure" Tourette syndrome?". J. Child Neurol. (Review). 21 (8): 701–703. doi:10.1177/08830738060210080701. PMID 16970871. S2CID 44775472.
63. ^ Denckla MB (2006). "Attention deficit hyperactivity disorder: the childhood co-morbidity that most influences the disability burden in Tourette syndrome". Adv Neurol (Review). 99: 17–21. PMID 16536349.
64. ^ Pruitt & Packer (2013), pp. 636–637.
65. ^ Baldermann JC, Schüller T, Huys D, et al. (2016). "Deep brain stimulation for Tourette syndrome: a systematic review and meta-analysis". Brain Stimul (Review). 9 (2): 296–304. doi:10.1016/j.brs.2015.11.005. PMID 26827109. S2CID 22929403.
66. ^ Cavanna AE (November 2018). "The neuropsychiatry of Gilles de la Tourette syndrome: The état de l'art". Rev. Neurol. (Paris) (Review). 174 (9): 621–627. doi:10.1016/j.neurol.2018.06.006. PMID 30098800. S2CID 51966823.
67. ^ Efron D, Dale RC (October 2018). "Tics and Tourette syndrome". J Paediatr Child Health (Review). 54 (10): 1148–1153. doi:10.1111/jpc.14165. hdl:11343/284621. PMID 30294996. S2CID 52934981.
68. Yu D, Sul JH, Tsetsos F, et al. (March 2019). "Interrogating the genetic determinants of Tourette's syndrome and other tic disorders through genome-wide association studies". Am J Psychiatry (Meta-analysis). 176 (3): 217–227. doi:10.1176/appi.ajp.2018.18070857. PMC 6677250. PMID 30818990.
69. van de Wetering BJ, Heutink P (May 1993). "The genetics of the Gilles de la Tourette syndrome: a review". J. Lab. Clin. Med. (Review). 121 (5): 638–645. PMID 8478592.
70. Paschou P (July 2013). "The genetic basis of Gilles de la Tourette Syndrome". Neurosci Biobehav Rev (Review). 37 (6): 1026–1039. doi:10.1016/j.neubiorev.2013.01.016. PMID 23333760. S2CID 10515751.
71. Barnhill J, Bedford J, Crowley J, Soda T (2017). "A search for the common ground between Tic; Obsessive-compulsive and Autism Spectrum Disorders: part I, Tic disorders". AIMS Genet (Review). 4 (1): 32–46. doi:10.3934/genet.2017.1.32. PMC 6690237. PMID 31435502.
72. ^ Hsu CJ, Wong LC, Lee WT (January 2021). "Immunological dysfunction in Tourette syndrome and related disorders". Int J Mol Sci (Review). 22 (2): 853. doi:10.3390/ijms22020853. PMC 7839977. PMID 33467014.
73. ^ Wilbur C, Bitnun A, Kronenberg S, Laxer RM, Levy DM, Logan WJ, Shouldice M, Yeh EA (May 2019). "PANDAS/PANS in childhood: Controversies and evidence". Paediatr Child Health. 24 (2): 85–91. doi:10.1093/pch/pxy145. PMC 6462125. PMID 30996598.
74. Sigra S, Hesselmark E, Bejerot S (March 2018). "Treatment of PANDAS and PANS: a systematic review". Neurosci Biobehav Rev. 86: 51–65. doi:10.1016/j.neubiorev.2018.01.001. PMID 29309797. S2CID 40827012.
75. Hirschtritt ME, Darrow SM, et al. (January 2018). "Genetic and phenotypic overlap of specific obsessive-compulsive and attention-deficit/hyperactive subtypes with Tourette syndrome". Psychol Med. 48 (2): 279–293. doi:10.1017/S0033291717001672. PMC 7909616. PMID 28651666. S2CID 26353939.
76. Walkup, Mink & Hollenback (2006), p. xv.
77. ^ Sukhodolsky et al. (2017), p. 246.
78. Cox JH, Seri S, Cavanna AE (May 2018). "Sensory aspects of Tourette syndrome" (PDF). Neurosci Biobehav Rev (Review). 88: 170–176. doi:10.1016/j.neubiorev.2018.03.016. PMID 29559228. S2CID 4640655. Archived (PDF) from the original on December 1, 2020. Retrieved March 18, 2020.
79. Rapanelli M, Pittenger C (July 2016). "Histamine and histamine receptors in Tourette syndrome and other neuropsychiatric conditions". Neuropharmacology (Review). 106: 85–90. doi:10.1016/j.neuropharm.2015.08.019. PMID 26282120. S2CID 20574808.
80. Rapanelli M (February 2017). "The magnificent two: histamine and the H3 receptor as key modulators of striatal circuitry". Prog. Neuropsychopharmacol. Biol. Psychiatry (Review). 73: 36–40. doi:10.1016/j.pnpbp.2016.10.002. PMID 27773554. S2CID 23588346.
81. Bolam JP, Ellender TJ (July 2016). "Histamine and the striatum". Neuropharmacology (Review). 106: 74–84. doi:10.1016/j.neuropharm.2015.08.013. PMC 4917894. PMID 26275849.
82. Sadek B, Saad A, Sadeq A, Jalal F, Stark H (October 2016). "Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases". Behav. Brain Res. (Review). 312: 415–430. doi:10.1016/j.bbr.2016.06.051. PMID 27363923. S2CID 40024812.
83. "DSM-5-TR Fact Sheets" (PDF). American Psychiatric Association. 2022. Archived (PDF) from the original on August 18, 2022. Retrieved July 9, 2022.
84. ^ Walkup JT, Ferrão Y, Leckman JF, Stein DJ, Singer H (June 2010). "Tic disorders: some key issues for DSM-V" (PDF). Depress Anxiety (Review). 27 (6): 600–610. doi:10.1002/da.20711. PMID 20533370. S2CID 5469830. Archived from the original (PDF) on January 20, 2012.
85. ^ Scahill L, Erenberg G, Berlin CM, et al. (April 2006). "Contemporary assessment and pharmacotherapy of Tourette syndrome". NeuroRx (Review). 3 (2): 192–206. doi:10.1016/j.nurx.2006.01.009. PMC 3593444. PMID 16554257.
86. ^ Sukhodolsky et al. (2017), p. 247.
87. ^ Bagheri MM, Kerbeshian J, Burd L (April 1999). "Recognition and management of Tourette's syndrome and tic disorders". Am Fam Physician (Review). 59 (8): 2263–2272, 2274. PMID 10221310. Archived from the original on March 31, 2005.
88. ^ "What is Tourette syndrome?" (PDF). Tourette Association of America. Archived (PDF) from the original on February 26, 2020. Retrieved January 19, 2020.
89. ^ Müller-Vahl (2013), p. 625.
90. ^ "Summary of Practice: Relevant changes to DSM-IV-TR". American Psychiatric Association. Archived from the original on May 11, 2008. Retrieved December 29, 2011.
91. ^ Horner O, Hedderly T, Malik O (August 2022). "The changing landscape of childhood tic disorders following COVID-19". Paediatr Child Health (Oxford). 32 (10): 363–367. doi:10.1016/j.paed.2022.07.007. PMC 9359930. PMID 35967969.
92. Martino D, Pringsheim TM, Cavanna AE, et al. (March 2017). "Systematic review of severity scales and screening instruments for tics: Critique and recommendations". Mov. Disord. (Review). 32 (3): 467–473. doi:10.1002/mds.26891. PMC 5482361. PMID 28071825.
93. ^ Sukhodolsky et al. (2017), p. 248.
94. ^ Mejia NI, Jankovic J (March 2005). "Secondary tics and tourettism" (PDF). Braz J Psychiatry. 27 (1): 11–17. doi:10.1590/s1516-44462005000100006. PMID 15867978. Archived from the original (PDF) on June 28, 2007.
95. Ringman JM, Jankovic J (June 2000). "Occurrence of tics in Asperger's syndrome and autistic disorder". J. Child Neurol. (Case report). 15 (6): 394–400. doi:10.1177/088307380001500608. PMID 10868783. S2CID 8596251.
96. ^ Jankovic J, Mejia NI (2006). "Tics associated with other disorders". Adv Neurol (Review). 99: 61–68. PMID 16536352.
97. Freeman RD. "Tourette's syndrome: minimizing confusion". Roger Freeman, MD, blog. Archived from the original on April 11, 2006. Retrieved February 8, 2006.
98. ^ Ganos C, Martino D, Espay AJ, Lang AE, Bhatia KP, Edwards MJ (October 2019). "Tics and functional tic-like movements: Can we tell them apart?" (PDF). Neurology (Review). 93 (17): 750–758. doi:10.1212/WNL.0000000000008372. PMID 31551261. S2CID 202761321. Archived (PDF) from the original on June 3, 2022. Retrieved April 3, 2022.
99. ^ Baizabal-Carvallo JF, Fekete R (2015). "Recognizing uncommon presentations of psychogenic (functional) movement disorders". Tremor Other Hyperkinet Mov (N Y) (Review). 5: 279. doi:10.7916/D8VM4B13. PMC 4303603. PMID 25667816.
100. ^ Thenganatt MA, Jankovic J (August 2019). "Psychogenic (functional) movement disorders". Continuum (Minneap Minn) (Review). 25 (4): 1121–1140. doi:10.1212/CON.0000000000000755. PMID 31356296. S2CID 198984465.
101. ^ Espay AJ, Aybek S, Carson A, et al. (September 2018). "Current concepts in diagnosis and treatment of functional neurological disorders". JAMA Neurol (Review). 75 (9): 1132–1141. doi:10.1001/jamaneurol.2018.1264. PMC 7293766. PMID 29868890.
102. Malaty IA, Anderson S, Bennett SM, et al. (October 2022). "Diagnosis and management of functional tic-like phenomena". J Clin Med. 11 (21): 6470. doi:10.3390/jcm11216470. PMC 9656241. PMID 36362696.
103. Frey J, Black KJ, Malaty IA (2022). "TikTok Tourette's: are we witnessing a rise in functional tic-like behavior driven by adolescent social media use?". Psychol Res Behav Manag. 15: 3575–3585. doi:10.2147/PRBM.S359977. PMC 9733629. PMID 36505669.
104. ^ Singer HS (March 2005). "Tourette's syndrome: from behaviour to biology". Lancet Neurol (Review). 4 (3): 149–159. doi:10.1016/S1474-4422(05)01012-4. PMID 15721825. S2CID 20181150.
105. Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, Agúndez JA (October 2020). "Sleep disorders in tourette syndrome". Sleep Med Rev (Review). 53: 101335. doi:10.1016/j.smrv.2020.101335. PMID 32554211. S2CID 219467176.
106. Spencer T, Biederman J, Harding M, et al. (October 1998). "Disentangling the overlap between Tourette's disorder and ADHD". J Child Psychol Psychiatry (Comparative study). 39 (7): 1037–1044. doi:10.1111/1469-7610.00406. PMID 9804036.
107. Morand-Beaulieu S, Leclerc JB (January 2020). "". Encephale (in French). 46 (2): 146–52. doi:10.1016/j.encep.2019.10.002. PMID 32014239. S2CID 226212092.
108. "Tourette syndrome treatments". U.S. Centers for Disease Control and Prevention (CDC). 2019. Archived from the original on February 26, 2020. Retrieved February 26, 2020.
109. ^ Pringsheim T, Okun MS, Müller-Vahl K, et al. (May 2019). "Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders". Neurology (Review). 92 (19): 896–906. doi:10.1212/WNL.0000000000007466. PMC 6537133. PMID 31061208.
110. ^ Müller-Vahl (2013), p. 628.
111. ^ Stern JS, Burza S, Robertson MM (January 2005). "Gilles de la Tourette's syndrome and its impact in the UK". Postgrad Med J (Review). 81 (951): 12–19. doi:10.1136/pgmj.2004.023614. PMC 1743178. PMID 15640424. Reassurance, explanation, supportive psychotherapy, and psychoeducation are important and ideally the treatment should be multidisciplinary. In mild cases the previous methods may be all that is required, supplemented with contact with the Tourette Syndrome Association where the patient or parents wish.
112. Robertson MM (March 2000). "Tourette syndrome, associated conditions and the complexities of treatment". Brain (Review). 123 (Pt 3): 425–462. doi:10.1093/brain/123.3.425. PMID 10686169.
113. Peterson BS, Cohen DJ (1998). "The treatment of Tourette's syndrome: multimodal, developmental intervention". J Clin Psychiatry (Review). 59 (Suppl 1): 62–74. PMID 9448671. Because of the understanding and hope that it provides, education is also the single most important treatment modality that we have in TS. Also see Zinner 2000, PMID 11077021.
114. ^ Müller-Vahl (2013), p. 623.
115. ^ Andrén P, Jakubovski E, Murphy TL, et al. (July 2021). "European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part II: psychological interventions". Eur Child Adolesc Psychiatry. 31 (3): 403–423. doi:10.1007/s00787-021-01845-z. PMC 8314030. PMID 34313861.
116. Müller-Vahl (2013), p. 626; "Quite often, the unimpaired child receives medical treatment to reduce tics, when instead the parents should more appropriately receive psychoeducation and social support to better cope with the condition".
117. ^ Pruitt & Packer (2013), pp. 646–647.
118. ^ Müller-Vahl (2013), p. 627.
119. Müller-Vahl (2013), p. 633.
120. ^ Fründt O, Woods D, Ganos C (April 2017). "Behavioral therapy for Tourette syndrome and chronic tic disorders". Neurol Clin Pract (Review). 7 (2): 148–156. doi:10.1212/CPJ.0000000000000348. PMC 5669407. PMID 29185535.
121. Sukhodolsky et al. (2017), p. 250.
122. ^ Bloch MH, Leckman JF (December 2009). "Clinical course of Tourette syndrome". J Psychosom Res (Review). 67 (6): 497–501. doi:10.1016/j.jpsychores.2009.09.002. PMC 3974606. PMID 19913654.
123. Woods DW, Himle MB, Conelea CA (2006). "Behavior therapy: other interventions for tic disorders". Adv Neurol (Review). 99: 234–240. PMID 16536371.
124. ^ Sukhodolsky et al. (2017), p. 251.
125. Roessner V, Eichele H, Stern JS, et al. (November 2021). "European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment". Eur Child Adolesc Psychiatry. 31 (3): 425–441. doi:10.1007/s00787-021-01899-z. PMC 8940878. PMID 34757514. S2CID 243866351.
126. Zinner SH (August 2004). "Tourette syndrome—much more than tics" (PDF). Contemporary Pediatrics. 21 (8): 22–49. Archived from the original (PDF) on September 30, 2007. Retrieved May 20, 2019.
127. Kumar A, Duda L, Mainali G, Asghar S, Byler D (2018). "A comprehensive review of Tourette syndrome and complementary alternative medicine". Curr Dev Disord Rep (Review). 5 (2): 95–100. doi:10.1007/s40474-018-0137-2. PMC 5932093. PMID 29755921.
128. Black N, Stockings E, Campbell G, et al. (December 2019). "Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis". Lancet Psychiatry. 6 (12): 995–1010. doi:10.1016/S2215-0366(19)30401-8. PMC 6949116. PMID 31672337.
129. Szejko N, Worbe Y, Hartmann A, et al. (October 2021). "European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part IV: deep brain stimulation". Eur Child Adolesc Psychiatry. 31 (3): 443–461. doi:10.1007/s00787-021-01881-9. PMC 8940783. PMID 34605960. S2CID 238254975.
130. Viswanathan A, Jimenez-Shahed J, Baizabal Carvallo JF, Jankovic J (2012). "Deep brain stimulation for Tourette syndrome: target selection". Stereotact Funct Neurosurg (Review). 90 (4): 213–224. doi:10.1159/000337776. PMID 22699684. Archived from the original on August 29, 2017. Retrieved January 25, 2020.
131. ^ Rabin ML, Stevens-Haas C, Havrilla E, Devi T, Kurlan R (February 2014). "Movement disorders in women: a review". Mov. Disord. (Review). 29 (2): 177–183. doi:10.1002/mds.25723. PMID 24151214. S2CID 27527571.
132. ^ Ba F, Miyasaki JM (2020). "Movement disorders in pregnancy". Neurology and Pregnancy: Neuro-Obstetric Disorders (Review). Handbook of Clinical Neurology. Vol. 172. pp. 219–239. doi:10.1016/B978-0-444-64240-0.00013-1. ISBN 9780444642400. PMID 32768090. S2CID 226513843.
133. ^ García-Ramos R, Santos-García D, Alonso-Cánovas, et al. (March 2021). "Management of Parkinson's disease and other movement disorders in women of childbearing age: Part 2". Neurologia (Engl Ed) (Review) (in Spanish). 36 (2): 159–168. doi:10.1016/j.nrl.2020.05.012. hdl:2445/175997. ISSN 0213-4853. PMID 32980194. S2CID 224905452.
134. ^ Kranick SM, Mowry EM, Colcher A, Horn S, Golbe LI (April 2010). "Movement disorders and pregnancy: a review of the literature". Mov. Disord. (Review). 25 (6): 665–671. doi:10.1002/mds.23071. PMID 20437535. S2CID 41160705.
135. Committee on Drugs: American Academy of Pediatrics (April 2000). "Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn". Pediatrics. 105 (4): 880–887. doi:10.1542/peds.105.4.880. PMID 10742343. Archived from the original on June 17, 2020. Retrieved June 17, 2020.
136. Baxter K (October 5, 2019). "Column: Tim Howard, whose career is likely to end Sunday, will retire as the best U.S. goalkeeper ever". Los Angeles Times. Archived from the original on December 25, 2019. Retrieved December 28, 2019.
137. ^ Howard T (December 6, 2014). "Tim Howard: Growing up with Tourette syndrome and my love of football". The Guardian. Archived from the original on November 15, 2016. Retrieved March 21, 2015.
138. ^ Novotny M, Valis M, Klimova B (2018). "Tourette syndrome: a mini-review". Front Neurol (Review). 9: 139. doi:10.3389/fneur.2018.00139. PMC 5854651. PMID 29593638.
139. Pappert EJ, Goetz CG, Louis ED, Blasucci L, Leurgans S (October 2003). "Objective assessments of longitudinal outcome in Gilles de la Tourette's syndrome". Neurology. 61 (7): 936–940. doi:10.1212/01.wnl.0000086370.10186.7c. PMID 14557563. S2CID 7815576.
140. ^ Evans J, Seri S, Cavanna AE (September 2016). "The effects of Gilles de la Tourette syndrome and other chronic tic disorders on quality of life across the lifespan: a systematic review". Eur Child Adolesc Psychiatry (Review). 25 (9): 939–948. doi:10.1007/s00787-016-0823-8. PMC 4990617. PMID 26880181.
141. Abi-Jaoude et al. (2009), p. 564.
142. Leckman & Cohen (1999), p. 37. "For example, individuals who were misunderstood and punished at home and at school for their tics or who were teased mercilessly by peers and stigmatized by their communities will fare worse than a child whose interpersonal environment was more understanding and supportive."
143. Cohen DJ, Leckman JF, Pauls D (1997). "Neuropsychiatric disorders of childhood: Tourette's syndrome as a model". Acta Paediatr Suppl. 422. Scandinavian University Press: 106–111. doi:10.1111/j.1651-2227.1997.tb18357.x. PMID 9298805. S2CID 19687202. The individuals with TS who do the best, we believe, are: those who have been able to feel relatively good about themselves and remain close to their families; those who have the capacity for humor and for friendship; those who are less burdened by troubles with attention and behavior, particularly aggression; and those who have not had development derailed by medication.
144. Müller-Vahl (2013), p. 630.
145. Gulati, S (2016). "Tics and Tourette Syndrome – Key Clinical Perspectives: Roger Freeman (ed)". Indian J Pediatr. 83 (11): 1361. doi:10.1007/s12098-016-2176-1. Tic disorder is a common neurodevelopmental disorder of childhood. It is one of the commonest condition encountered by a pediatrician in office practice, especially in developed countries.
146. Cohen, Jankovic & Goetz (2001), p. xviii.
147. Abuzzahab FE, Anderson FO (June 1973). "Gilles de la Tourette's syndrome; international registry". Minn Med. 56 (6): 492–496. PMID 4514275.
148. ^ Scahill L. "Epidemiology of tic disorders" (PDF). Medical letter: 2004 retrospective summary of TS literature. Tourette Syndrome Association. Archived from the original (PDF) on December 25, 2010. Retrieved June 11, 2007.
149. See also Zohar AH, Apter A, King RA, et al (1999). "Epidemiological studies" in Leckman & Cohen (1999), pp. 177–192.
150. Hawley JS (June 23, 2008). "Tourette syndrome". eMedicine. Archived from the original on August 4, 2009. Retrieved August 10, 2009.
151. Leckman JF (November 2002). "Tourette's syndrome". Lancet (Review). 360 (9345): 1577–1586. doi:10.1016/S0140-6736(02)11526-1. PMID 12443611. S2CID 27325780.
152. Itard J (1825). "Mémoire sur quelques functions involontaires des appareils de la locomotion, de la préhension et de la voix". Arch Gen Med. 8: 385–407. As cited in Newman S (September 2006). "'Study of several involuntary functions of the apparatus of movement, gripping, and voice' by Jean-Marc Gaspard Itard (1825)" (PDF). History of Psychiatry. 17 (67 Pt 3): 333–339. doi:10.1177/0957154X06067668. PMID 17214432. S2CID 44541188. Archived (PDF) from the original on January 25, 2020. Retrieved January 25, 2020.
153. Walusinski (2019), pp. 167–169.
154. "What is Tourette syndrome?". Tourette Syndrome Association. Archived from the original on January 14, 2012. Retrieved January 14, 2012.
155. Walusinski (2019), pp. xvii–xviii, 23.
156. Rickards H, Cavanna AE (December 2009). "Gilles de la Tourette: the man behind the syndrome". Journal of Psychosomatic Research. 67 (6): 469–474. doi:10.1016/j.jpsychores.2009.07.019. PMID 19913650.
157. Gilles de la Tourette G, Goetz CG, Llawans HL (1982). "Étude sur une affection nerveuse caractérisée par de l'incoordination motrice accompagnée d'echolalie et de coprolalie". Advances in Neurology: Gilles de la Tourette Syndrome. 35: 1–16. As discussed at Black KJ (March 30, 2007). "Tourette syndrome and other tic disorders". eMedicine. Archived from the original on August 22, 2009. Retrieved August 10, 2009.
158. Robertson MM, Reinstein DZ (1991). "Convulsive tic disorder: Georges Gilles de la Tourette, Guinon and Grasset on the phenomenology and psychopathology of Gilles de la Tourette syndrome" (PDF). Behavioural Neurology. 4 (1): 29–56. doi:10.1155/1991/505791. PMID 24487352. Archived (PDF) from the original on November 25, 2020. Retrieved June 17, 2020.
159. Walusinski (2019), pp. xi, 398: "Interne: House physician or house officer. The internes lived at the hospital and had diagnostic and therapeutic responsibilities. Chef de Clinique: Senior house officer or resident. In 1889, when Gilles de la Tourette was Chef de Clinique under Charcot ... ".
160. ^ Blue T (2002). Tourette syndrome. Essortment, Pagewise Inc. Retrieved on August 10, 2009.
161. Rickards H, Hartley N, Robertson MM (September 1997). "Seignot's paper on the treatment of Tourette's syndrome with haloperidol. Classic Text No. 31". Hist Psychiatry (Historical biography). 8 (31 Pt 3): 433–436. doi:10.1177/0957154X9700803109. PMID 11619589. S2CID 2009337.
162. Gadow KD, Sverd J (2006). "Attention deficit hyperactivity disorder, chronic tic disorder, and methylphenidate". Adv Neurol (Review). 99: 197–207. PMID 16536367.
163. Brody JE (May 29, 1975). "Bizarre outbursts of Tourette's disease victims linked to chemical disorder in brain". The New York Times. Archived from the original on February 12, 2020. Retrieved January 19, 2020.
164. Kushner (2000), pp. 142–143, 187, 204, 208–212.
165. Cohen DJ, Leckman JF (January 1994). "Developmental psychopathology and neurobiology of Tourette's syndrome". J Am Acad Child Adolesc Psychiatry (Review). 33 (1): 2–15. doi:10.1097/00004583-199401000-00002. PMID 8138517. interactions among genetic factors, neurobiological substrates, and environmental factors in the production of the clinical phenotypes. The genetic vulnerability factors that underlie Tourette's syndrome and other tic disorders undoubtedly influence the structure and function of the brain, in turn producing clinical symptoms. Available evidence ... also indicates that a range of epigenetic or environmental factors ... are critically involved in the pathogenesis of these disorders.
166. Leckman & Cohen (1999), p. 408.
167. Leckman & Cohen (1999), pp. 18–19, 148–151, 408.
168. Müller-Vahl (2013), p. 624; "... a few 'positive' aspects may be closely linked to TS. People with TS, for example, may have positive personality characteristics and talents such as punctuality, correctness, conscientiousness, a sense of justice, quick comprehension, good intelligence, creativity, musicality, and athletic abilities. For that reason, some people with TS even hesitate when asked whether they wish the disorder would disappear completely".
169. Portraits of adults with TS. Tourette Syndrome Association. Retrieved from July 16, 2011, archive.org version on December 21, 2011.
170. Keilman J (January 22, 2015). "Reviews: The Game of Our Lives by David Goldblatt, The Keeper by Tim Howard". Chicago Tribune. Archived from the original on April 2, 2015. Retrieved March 21, 2015.
171. Tim Howard receives first-ever Champion of Hope Award from the National Tourette Syndrome Association. Archived March 30, 2015, at the Wayback Machine Tourette Syndrome Association. October 14, 2014. Retrieved on March 21, 2015.
172. Samuel Johnson. Tourette Syndrome Association. Retrieved from April 7, 2005, archive.org version on December 30, 2011.
173. Pearce JM (July 1994). "Doctor Samuel Johnson: 'the great convulsionary' a victim of Gilles de la Tourette's syndrome". J R Soc Med (Historical biography). 87 (7): 396–399. doi:10.1177/014107689408700709. PMC 1294650. PMID 8046726.
174. Powell H, Kushner HI (2015). "Mozart at play: the limitations of attributing the etiology of genius to tourette syndrome and mental illness". Prog. Brain Res. (Historical biography). 216: 277–291. doi:10.1016/bs.pbr.2014.11.010. PMID 25684294.
175. Bhattacharyya KB, Rai S (2015). "Famous people with Tourette's syndrome: Dr. Samuel Johnson (yes) & Wolfgang Amadeus Mozart (may be): Victims of Tourette's syndrome?". Ann Indian Acad Neurol. 18 (2): 157–161. doi:10.4103/0972-2327.145288. PMC 4445189. PMID 26019411.
176. Simkin B (1992). "Mozart's scatological disorder". BMJ (Historical biography). 305 (6868): 1563–1567. doi:10.1136/bmj.305.6868.1563. PMC 1884718. PMID 1286388. Also see: Simkin, Benjamin. Medical and musical byways of Mozartiana. Fithian Press. 2001. ISBN 1-56474-349-7 Review Archived December 7, 2005, at the Wayback Machine, Retrieved on May 14, 2007.
177. Mozart:
     • Kammer T (2007). "Mozart in the neurological department – who has the tic?" (PDF). In Bogousslavsky J, Hennerici MG (eds.). Neurological Disorders in Famous Artists - Part 2 (Historical biography). Frontiers of Neurology and Neuroscience. Vol. 22. Basel: Karger. pp. 184–192. doi:10.1159/000102880. ISBN 978-3-8055-8265-0. PMID 17495512. Archived from the original (PDF) on February 7, 2012.
     • Ashoori A, Jankovic J (November 2007). "Mozart's movements and behaviour: a case of Tourette's syndrome?". J. Neurol. Neurosurg. Psychiatry (Historical biography). 78 (11): 1171–1175. doi:10.1136/jnnp.2007.114520. PMC 2117611. PMID 17940168.
     • Sacks O (1992). "Tourette's syndrome and creativity". BMJ (Editorial comment). 305 (6868): 1515–1516. doi:10.1136/bmj.305.6868.1515. PMC 1884721. PMID 1286364.
178. Voss H (October 2012). "The representation of movement disorders in fictional literature". J. Neurol. Neurosurg. Psychiatry (Review). 83 (10): 994–999. doi:10.1136/jnnp-2012-302716. PMID 22752692. S2CID 27902880.
179. Calder-Sprackman S, Sutherland S, Doja A (March 2014). "Tourette syndrome in film and television". The Canadian Journal of Neurological Sciences. 41 (2): 226–232. doi:10.1017/S0317167100016620. PMID 24534035. S2CID 39288755.
180. Lim Fat MJ, Sell E, Barrowman N, Doja A (2012). "Public perception of Tourette syndrome on YouTube". Journal of Child Neurology. 27 (8): 1011–1016. CiteSeerX 10.1.1.997.9069. doi:10.1177/0883073811432294. PMID 22821136. S2CID 21648806.
181. Holtgren B (January 11, 2006). "Truth about Tourette's not what you think". Cincinnati Enquirer. As medical problems go, Tourette's is, except in the most severe cases, about the most minor imaginable thing to have. ... the freak-show image, unfortunately, still prevails overwhelmingly. The blame for the warped perceptions lies overwhelmingly with the video media—the Internet, movies and TV. If you search for 'Tourette' on Google or YouTube, you'll get a gazillion hits that almost invariably show the most outrageously extreme examples of motor and vocal tics. Television, with notable exceptions such as Oprah, has sensationalized Tourette's so badly, for so long, that it seems beyond hope that most people will ever know the more prosaic truth.
182. US media:
     • "Oprah and Dr. Laura" (Press release). Tourette Syndrome Association. May 31, 2001. Archived from the original on October 6, 2001. Retrieved December 21, 2011.
     • "Letter of response to Dr. Phil" (Press release). Tourette Syndrome Association. Archived from the original on August 31, 2008. Retrieved December 21, 2011.
     • "Letter of response to Garrison Keillor radio show" (Press release). Tourette Syndrome Association. Archived from the original on February 7, 2009. Retrieved December 21, 2011.
183. Guldberg H (May 26, 2006). "Stop celebrating Tourette's". Spiked. Archived from the original on March 14, 2017. Retrieved December 26, 2006.
184. Swerdlow NR (September 2005). "Tourette syndrome: current controversies and the battlefield landscape". Curr Neurol Neurosci Rep. 5 (5): 329–331. doi:10.1007/s11910-005-0054-8. PMID 16131414. S2CID 26342334.
185. Fernandez TV, State MW, Pittenger C (2018). "Tourette disorder and other tic disorders". Neurogenetics, Part I (Review). Handbook of Clinical Neurology. Vol. 147. pp. 343–354. doi:10.1016/B978-0-444-63233-3.00023-3. ISBN 978-0-444-63233-3. PMID 29325623. Regardless of whether the focus is on discovering rare or common sequence or structural genetic variation, it is clear that large collections of biomaterials (likely in the tens of thousands) that are accessible by multiple research groups will be essential for success. Three consortia are now beginning to work toward this goal (TSAICG and TIC Genetics in the United States, and EMTics in the European Union); there is active collaboration among these groups, which will also be essential for success. However, the scale of the funded collection efforts, particularly in the United States, remains quite modest compared to other neuropsychiatric disorders in which there has been success in gene discovery.

Book sources

• Abi-Jaoude E, Kideckel D, Stephens R, et al. (2009). "Tourette syndrome: a model of integration". In Carlstedt RA (ed.). Handbook of Integrative Clinical Psychology, Psychiatry, and Behavioral Medicine: Perspectives, Practices, and Research. New York: Springer Publishing Company. ISBN 978-0-8261-1095-4.
• Cohen DJ, Jankovic J, Goetz CG, eds. (2001). Tourette Syndrome. Advances in Neurology. Vol. 85. Philadelphia, PA: Lippincott Williams & Wilkins. ISBN 0-7817-2405-8.
• Kushner HI (2000). A Cursing Brain?: The Histories of Tourette Syndrome. Harvard University Press. ISBN 0-674-00386-1.
• Leckman JF, Cohen DJ (1999). Tourette's Syndrome—Tics, Obsessions, Compulsions: Developmental Psychopathology and Clinical Care. New York: John Wiley & Sons, Inc. ISBN 978-0471160373.
• Martino D, Leckman JF, eds. (2013). Tourette syndrome. Oxford University Press. ISBN 978-0199796267.
  • Bloch MH (2013). "Clinical course and adult outcome in Tourette syndrome". In Martino D, Leckman JF (eds.). Tourette syndrome. Oxford University Press. pp. 107–120.
  • Müller-Vahl KR (2013). "Information and social support for patients and families". In Martino D, Leckman JF (eds.). Tourette syndrome. Oxford University Press. pp. 623–635.
  • Pruitt SK, Packer LE (2013). "Tourette syndrome". In Martino D, Leckman JF (eds.). Information and support for educators. Oxford University Press. pp. 636–655.
• Sukhodolsky DG, Gladstone TR, Kaushal SA, Piasecka JB, Leckman JF (2017). "Tics and Tourette Syndrome". In Matson JL (ed.). Handbook of Childhood Psychopathology and Developmental Disabilities Treatment. Autism and Child Psychopathology Series. Springer. pp. 241–256. doi:10.1007/978-3-319-71210-9_14. ISBN 978-3-319-71209-3.
• Walkup JT, Mink JW, Hollenback PJ, eds. (2006). Advances in Neurology, Tourette Syndrome. Vol. 99. Philadelphia, PA: Lippincott Williams & Wilkins. ISBN 0-7817-9970-8.
• Walusinski O (2019). Georges Gilles de la Tourette: Beyond the Eponym, a Biography. Oxford University Press. ISBN 978-0-19-063603-6.

Further reading

• McGuire JF, Murphy TK, Piacentini J, Storch EA (2018). The Clinician's Guide to Treatment and Management of Youth with Tourette Syndrome and Tic Disorders. Academic Press. ISBN 978-0128119808.
• Olson S (September 2004). "Neurobiology. Making sense of Tourette's". Science. 305 (5689): 1390–92. doi:10.1126/science.305.5689.1390. PMID 15353772. S2CID 177963554.

External links

• Template:Curlie

• Tourette syndrome
• Mental disorders diagnosed in childhood
• Neurogenetic disorders